# Kernal Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kernal-biologics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.kernalbio.com
- Total disclosed funding: $27M
- Latest round: Seed (Feb 10, 2022)
- Investors on record: 7

## About

Founded in 2016 by its CEO, Yusuf Erkul, and president, Burak Yilmaz, and based in Massachusetts, US, Kernal Biologics, Inc., operates as a biotechnology company that creates mRNA therapies to cure diseases like COVID and cancer. In February 2022, Kernal Biologics, Inc., raised USD 20 million in series A funding led by returning investor Hummingbird Ventures, with participation from other returning investors Amino Collective and Civilization Ventures.

Kernal Biologics uses deep learning to create mRNA therapies that will instruct cells on how to create their own medicine. The firm is currently developing mRNA technology that targets SARS-Cov-2 and opens an mRNA platform that will work on developing vaccines for COVID-19.

The company plans to use the February 2022 funding to expand its mRNA 2.0 platform and support its IND for immuno-oncology candidate KR-335.

## Funding rounds

- Seed, Feb 10, 2022, $20M — Amgen Ventures, Hummingbird Ventures, FoundersX Ventures, Civilization Ventures, Amino Collective
- Seed, Oct 25, 2020, $6.7M — FoundersX Ventures
- Seed, Oct 25, 2020 — Hummingbird Ventures, Civilization Ventures, Calm/Storm Ventures, Scale Asia Ventures

## Investors

- FoundersX Ventures (https://capitalatlas.ai/funds/foundersx-ventures) — Seed
- Hummingbird Ventures (https://capitalatlas.ai/funds/hummingbird-ventures) — Seed
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Seed
- Calm/Storm Ventures (https://capitalatlas.ai/funds/calm-storm-ventures) — Seed
- Scale Asia Ventures (https://capitalatlas.ai/funds/scale-asia-ventures) — Seed
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Seed
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed